Tag: AHA 2023
VOYAGER PAD analyses shed light on use of rivaroxaban in high-risk patient populations
New analyses from the VOYAGER PAD clinical trial in both high-risk and fragile patients and thos...
AHA 2023: RCE Technologies wins Health Tech competition
RCE Technologies, the developer of a non-invasive, instant measurement of cardiac proteins was s...
SELECT trial shows cardiovascular risk reduction in non-diabetics taking semaglutide
Results of the SELECT clinical trial, presented at the American Heart Association’s 2023 Scientific ...
PCI improves angina symptoms without medication in ORBITA-2 trial
Percutaneous coronary intervention (PCI) relieves stable chest pain and improves exercise capaci...
